TB-500 dosing research protocols & reconstitution

“What dose of TB-500?” is asked far more often than the literature can honestly answer. Unlike better-mapped peptides, TB-500 (Thymosin β4) has no dose-finding consensus — what exists are the specific figures particular studies used, mostly in rats and in cell culture. This spoke reports those figures as a research reference, walks through the bacteriostatic-water reconstitution question (a useful contrast with BPC-157), and shows the syringe math. It is a research-protocol reference, not a human dosing recommendation.

The honest dosing picture

The defining feature of the TB-500 dosing question is how little there is to cite. There is no published dose-finding programme that establishes a recommended amount, no agreed milligram figure, and certainly no validated human dose. What the literature contains instead are the specific quantities and routes that individual studies happened to use to demonstrate a biological effect — almost all of them in rodents or in cell culture. Treating any of those numbers as a protocol for people is an extrapolation the evidence does not license.

There is no validated human dose for TB-500. The figures circulating online are extrapolations from rat and in-vitro studies — they describe what a particular experiment used, not what is established for any human purpose.

This matters more for TB-500 than for many peptides, because the parent compound — Thymosin β4 — reached phase-2 clinical investigation under RegeneRx without ever producing an approved dose for any indication. So even the clinical record, where it exists, is a set of trial doses that did not advance to registration rather than a settled regimen. TB-500 is not an approved medicine; everything below is a research reference.

What the studies actually used

The most-cited dose-relevant work is the 1999 study by Malinda and colleagues in the Journal of Investigative Dermatology, which administered Thymosin β4 both topically and by intraperitoneal injection in rat full-thickness wound-repair models, and accompanied the animal work with a cell-migration assay [1]. The piece of that paper most useful as a dose-response reference is the in-vitro arm: in a Boyden-chamber migration assay, keratinocyte migration was stimulated roughly two- to three-fold by as little as ~10 picograms of Tβ4 — a striking sensitivity, and about the closest thing to dose-response data in the whole record.

• Route — topical and intraperitoneal. The rat wound-repair work used both surface application and IP injection; the systemic and topical arms both produced effects in the model [1].
• In-vitro sensitivity — picogram scale. Keratinocyte migration responded to ~10 pg in the Boyden-chamber assay — orders of magnitude below anything quoted as a “dose” online, and a reminder that cell-culture potency does not translate to a body-weight protocol.
• Formulation context. The translational record for Tβ4 includes a topical ophthalmic eye-drop formulation explored for clinical use, which illustrates how the same molecule is dosed by concentration in a delivered volume rather than by a fixed milligram amount [2].
• Cardioprotection models. Reviews of the cardiac literature describe systemic administration of Tβ4 in injury models; here too the reported amounts are study-specific and expressed per animal, not as a human regimen [3].

The through-line is that every usable figure is the figure from one experiment, in one species or one cell type, for one readout. None of them constitutes a dose-finding consensus, and none translates to a validated human dose.

Reconstitution & diluent: bacteriostatic water

Reconstitution is where TB-500 is genuinely simpler than its frequent cluster-mate BPC-157. TB-500 (Thymosin β4) reconstitutes with standard bacteriostatic water — sterile water containing ~0.9% benzyl alcohol as a preservative — which keeps the diluted material usable across the multi-dose window a single vial implies. This is the useful contrast point: where BPC-157 protocols favour an acidic acetic-acid water for extended stability, TB-500 has no such requirement and uses the ordinary neutral-pH bacteriostatic diluent that most research peptides use.

The mechanics are the same as for any lyophilised peptide: introduce the diluent slowly down the inside wall of the vial rather than aiming the stream at the powder cake, then swirl gently to dissolve — never shake, which can shear and denature a longer peptide like full 43-residue Tβ4. Reconstituted material is generally kept refrigerated at 2–8°C and protected from light. The general diluent and documentation framework is in our reconstitution & CoA guide.

Related reading in the TB-500 cluster

For how TB-500 is proposed to act, see TB-500 mechanism research. For the clinical-trial and cardiac-model record behind these administration contexts, see TB-500 clinical & cardiac research. For the diluent contrast that makes BPC-157 the exception rather than the rule, see BPC-157 dosing research protocols and the general reconstitution & CoA guide. Overview: TB-500 synopsis · research peptides in the UAE · supply: TB-500 5 mg research-consultation page.

Further reading

Peer-reviewed citations used inline:

• [1] Malinda, et al. — J Invest Dermatol 1999. Thymosin β4 accelerates wound healing (topical/intraperitoneal rat model; keratinocyte migration stimulated by ~10 pg in vitro — the closest dose-response data). DOI 10.1046/j.1523-1747.1999.00708.x.
• [2] Sosne — Expert Opin Biol Ther 2018. Thymosin β4 ophthalmic formulation and clinical-translation context. DOI 10.1080/14712598.2018.1486818.
• [3] Pipes, et al. — Vitam Horm 2016. Thymosin β4 in cardioprotection models (administration context). DOI 10.1016/bs.vh.2016.04.004.

Last reviewed 11 June 2026. Wellness Labs supplies TB-500 as research-grade lyophilised powder for non-clinical investigation. Editorial inbox: info@uaewellnesslab.com.